

## Supplementary material

*Tabel S1: Summary of studies investigating the antagonistic effect of erenumab on  $\alpha$ -CGRP induced responses on CGRP-R and AMY<sub>1</sub>-R.*

Cell type	Receptor	Response	pIC <sub>50</sub> <sup>(I)</sup> , pEC <sub>50</sub> <sup>(E)</sup> or pA <sub>2</sub> <sup>(A)</sup>	CGRP-R /AMY <sub>1</sub> -R	Reference
<b>MCF-7</b>	AMY <sub>1</sub> -R	cAMP (calcitonin)	6.68 <sup>(I)</sup>	-	[13]
<b>SK-N-MC</b>	CGRP-R	cAMP	8.64 <sup>(I)</sup>	-	[13]
	CGRP-R	cAMP	7.13 <sup>(I)</sup>	-	[14]
<b>HEK 293</b>	CGRP-R	Flow cytometry binding	8.64 <sup>(E)</sup>	18	[14]
	AMY <sub>1</sub> -R		7.38 <sup>(E)</sup>		
<b>Oocytes</b>	CGRP-R + CFTR	Chloride current ( $\alpha$ -CGRP <sub>8-37</sub> )	8.4 <sup>(A)</sup>	-	[9]
	CGRP-R AMY <sub>1</sub> -R	Chloride current	10.86 <sup>(I)</sup> 9.35 <sup>(I)</sup>	32	La Cour et al. Current study

*If nothing else is mentioned in the response column, the agonist used is  $\alpha$ -CGRP and the antagonist is erenumab.*

*Tabel S2: Summary of studies investigating the antagonistic effect of rimegepant on  $\alpha$ -CGRP induced responses on CGRP-R and AMY<sub>1</sub>-R.*

Cell type	Receptor	Response	pIC <sub>50</sub>	Ratio CGRP-R /AMY <sub>1</sub> -R	References
<b>Cos7</b>	CGRP AMY <sub>1</sub> -R	cAMP	8.00 6.77	17	[15]
<b>Oocytes</b>	CGRP-R AMY <sub>1</sub> -R	Chloride current	11.30 9.91	25	La Cour et al. Current study